We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+4.02%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$14.7B
AUM Growth
-$14.5M
Cap. Flow
+$16.2M
Cap. Flow %
0.11%
Top 10 Hldgs %
85.95%
Holding
111
New
8
Increased
15
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$115M
2
IGMS
IGM Biosciences
IGMS
+$63.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$47.4M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$26.6M
5
URGN icon
UroGen Pharma
URGN
+$24.4M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$132M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$113M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$6.49M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.15M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 99.6%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCEL
26
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$43.2M 0.29%
3,532,760
– –
GWPH
27
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$42.7M 0.29%
370,845
– –
ZYME icon
28
Zymeworks
ZYME
$2.05B
$42.4M 0.29%
1,708,472
– –
BOLD
29
DELISTED
Audentes Therapeutics, Inc
BOLD
$42.3M 0.29%
1,506,438
– –
INSM icon
30
Insmed
INSM
$27.5B
$39.3M 0.27%
2,229,760
-232,456
-9% -$4.49M
BCRX icon
31
BioCryst Pharmaceuticals
BCRX
$2.44B
$36.5M 0.25%
12,725,472
-1,657,201
-12% -$5.15M
ADPT icon
32
Adaptive Biotechnologies
ADPT
$4.15B
$36M 0.25%
1,165,411
– –
KRYS icon
33
Krystal Biotech
KRYS
$10.3B
$35.9M 0.24%
1,034,674
– –
NGNE icon
34
Neurogene
NGNE
$773M
$32.2M 0.22%
565,284
+18,576
+3% +$1.13M
CBAY
35
DELISTED
Cymabay Therapeutics
CBAY
$29.2M 0.2%
5,707,411
– –
ALLK
36
DELISTED
Allakos
ALLK
$26.7M 0.18%
+339,690
New +$22.4M
KNSA icon
37
Kiniksa Pharmaceuticals
KNSA
$6.17B
$23.8M 0.16%
2,799,577
– –
MRUS
38
DELISTED
Merus
MRUS
$20.7M 0.14%
1,160,014
– –
QURE icon
39
uniQure
QURE
$3.36B
$20.4M 0.14%
517,700
– –
URGN icon
40
UroGen Pharma
URGN
$2.29B
$17.8M 0.12%
+747,751
New +$24.4M
AXSM icon
41
Axsome Therapeutics
AXSM
$10.9B
$15.6M 0.11%
772,286
– –
XNCR icon
42
Xencor
XNCR
$2.07B
$14.4M 0.1%
428,120
– –
AIMT
43
DELISTED
Aimmune Therapeutics
AIMT
$14.1M 0.1%
673,908
– –
PTGX icon
44
Protagonist Therapeutics
PTGX
$9.99B
$14.1M 0.1%
1,174,282
+179,200
+18% +$2.26M
LJPC
45
DELISTED
La Jolla Pharmaceutical Company
LJPC
$13.7M 0.09%
1,559,231
– –
ACGN
46
DELISTED
Aceragen Inc
ACGN
$13.3M 0.09%
271,376
+174
+0.1% +$7.64K
SYRE icon
47
Spyre Therapeutics
SYRE
$9.39B
$13.2M 0.09%
68,544
– –
ALKS icon
48
Alkermes
ALKS
$8.11B
$12.2M 0.08%
625,030
+225,030
+56% +$4.9M
SYRS
49
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$10.1M 0.07%
97,484
– –
SGMO
50
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.05M 0.06%
999,823
– –
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2019 Portfolio in Review

As of Q3 2019, Julian Baker held 111 positions worth $14.7B, down 0.1% from $14.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q3 2019 filing shows 8 new, 15 increased, 6 reduced and 2 closed positions. Its largest new stake was IGM Biosciences: 3,144,000 shares worth $55.8M. The largest sale was Array Biopharma Inc, an estimated $132M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Technology.

  • Julian Baker's largest Q3 2019 buy was IGM Biosciences: 3,144,000 shares worth $55.8M.
  • Julian Baker added most to Invitae Corporation in Q3 2019, an estimated $115M increase.
  • Julian Baker's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $113M.
  • Julian Baker fully exited Array Biopharma Inc in Q3 2019, selling an estimated $132M.
  • Julian Baker's ten largest holdings make up 86% of its $14.7B portfolio in Q3 2019.
  • Julian Baker opened 8 new positions and closed 2 in Q3 2019.
  • Julian Baker's portfolio value fell 0.1% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.